
-
Aurinia Pharmaceuticals NasdaqGM:AUPH Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Location: #140, 14315 – 118 Avenue, Edmonton, AB, T5L 4S6, Canada | Website: https://www.auriniapharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
821.8M
Cash
312.6M
Avg Qtr Burn
N/A
Short % of Float
8.57%
Insider Ownership
9.73%
Institutional Own.
45.61%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Lupkynis (Voclosporin) Details Lupus nephritis | Approved Quarterly sales | |
AUR200 Details Autoimmune disease | Phase 1 Data readout | |
Voclosporin Details Focal segmental glomerulosclerosis | Failed Discontinued | |
Voclosporin Ophthalmic Solution Details Dry eye syndrome | Failed Discontinued |